JSB Market Research

Paclitaxel was the first cancer medication to make it to cancer blockbuster drugs market with more than $1 billion in sales. The median price of the new cancer medication crossed $150 thousand which was launched in the year 2017, as per the recent pharmaceutical market research reports .  In the global oncology drug blockbuster market, the US observed a rapid increase in the spending of cancer treatments. This is a case for more than 5 years reaching around $50 billion in the year 2017. This accumulates to more than 50% of the total drug cost in the rest of the world which is around $60 billion. In the Global Oncology/Cancer Blockbuster Drugs Market , the treatments launched in the last five years have brought increased revenue in the global industry.  The following are the 10 Best-Selling Cancer Drugs of 2018.  10. Xtandi® (enzalutamide) Astellas Pharma and Pfizer - Androgen receptor inhibitor 9. Ibrance® (palbociclib) Pfizer - Kinase inhi...

The global 27 cancer blockbuster drugs market size is set to surpass US$ 120 billion by 2025. “ Global Oncology/Cancer Blockbuster Drugs Market Research Report 2019 - 2025” presents an in-depth assessment of the global  cancer blockbuster drugs market  dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future  outlook for global cancer blockbuster drugs  market. The report includes historical data from 2015 to 2018 and forecasts until 2025. The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025.The report provides clear insight into current and future developments of the global cancer blockbuster drugs market. The report explores detailed analysis of top 27 drugs market assessment globally from 2015 to 2018 and forecasts...